|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Logicbio Therapeutics, Inc. (LOGC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,180,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile LogicBio Therapeutics is a clinical-stage genetic medicine company focused on genome editing and gene delivery platforms to address diseases from infancy through adulthood. Co.'s genome editing platform, GeneRide™, is an approach to gene insertion harnessing a cell's natural deoxyribonucleic acid repair process. Co.'s product candidate, LB-001, is a single-administration, genome editing therapy developed using its GeneRide technology for the treatment of methylmalonic acidemia in pediatric patients. Co.'s other product candidate, LB-401 is based on its GeneRide technology. LB-401 is a genome editing therapy being developed for the treatment of hereditary tyrosinemia type 1 in newborns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-09-25 |
4 |
S |
$7.08 |
$1,232,948 |
I/I |
(174,219) |
2,655,020 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-09-24 |
4 |
S |
$7.63 |
$293,823 |
I/I |
(38,514) |
2,829,239 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-08-13 |
4 |
S |
$8.75 |
$1,391 |
I/I |
(159) |
2,867,753 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-08-12 |
4 |
S |
$8.79 |
$11,735 |
I/I |
(1,335) |
2,867,912 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-07-29 |
4 |
S |
$8.78 |
$23,788 |
I/I |
(2,709) |
2,869,247 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-07-22 |
4 |
S |
$9.00 |
$203,950 |
I/I |
(22,651) |
2,871,956 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-07-20 |
4 |
S |
$9.25 |
$342,056 |
I/I |
(36,983) |
2,894,607 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-07-17 |
4 |
S |
$9.24 |
$287,373 |
I/I |
(31,101) |
2,931,590 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-07-16 |
4 |
S |
$8.56 |
$139,786 |
I/I |
(16,332) |
2,962,691 |
|
- |
|
| Wilton Thomas |
Chief Business Officer |
• – – |
2019-08-27 |
4 |
OE |
$0.73 |
$54,750 |
D/D |
75,000 |
75,000 |
|
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2018-10-23 |
4 |
B |
$10.00 |
$7,000,000 |
I/I |
700,000 |
2,979,023 |
1.5 |
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2018-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,279,023 |
2,279,023 |
|
- |
|
| Ioannidou Sofia |
Director |
– • – |
2018-10-23 |
4 |
B |
$10.00 |
$4,200,000 |
I/I |
420,000 |
1,787,413 |
2.1 |
- |
|
| Ioannidou Sofia |
Director |
– • – |
2018-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,367,413 |
1,367,413 |
|
- |
|
| Orbimed Israel Gp Ii, L.p. |
Director |
– • • |
2018-10-23 |
4 |
B |
$10.00 |
$11,900,000 |
I/I |
1,190,000 |
6,466,783 |
2.25 |
- |
|
| Orbimed Israel Gp Ii, L.p. |
Director |
– • • |
2018-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
5,276,783 |
5,276,783 |
|
- |
|
| Kariv Tomer |
Director |
– • – |
2018-10-23 |
4 |
B |
$10.00 |
$4,200,000 |
I/I |
420,000 |
1,787,413 |
2.1 |
- |
|
| Kariv Tomer |
Director |
– • – |
2018-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,367,413 |
1,367,413 |
|
- |
|
| Oconnell Daniel P |
Director |
– • – |
2018-10-23 |
4 |
B |
$10.00 |
$7,000,000 |
I/I |
700,000 |
2,979,023 |
2.1 |
- |
|
| Oconnell Daniel P |
Director |
– • – |
2018-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,279,023 |
2,279,023 |
|
- |
|
| Chimovits Erez |
Director |
– • – |
2018-10-23 |
4 |
B |
$10.00 |
$4,900,000 |
I/I |
490,000 |
3,487,760 |
2.1 |
- |
|
| Chimovits Erez |
Director |
– • – |
2018-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,997,760 |
2,997,760 |
|
- |
|
47 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
